Hemab Therapeutics Holdings, Inc.’s Lock-Up Period Set To End on October 28th (NASDAQ:COAG)

Hemab Therapeutics’ (NASDAQ:COAG) lock-up period will expire on Wednesday, October 28th. Hemab Therapeutics had issued 16,750,000 shares in its initial public offering on May 1st. The total size of the offering was $301,500,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Analysts Set New Price Targets

A number of research firms recently commented on COAG. Jefferies Financial Group upped their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wedbush raised their target price on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Weiss Ratings downgraded Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. Rodman & Renshaw started coverage on Hemab Therapeutics in a research report on Monday, October 12th. They issued a “buy” rating and a $56.00 target price on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Hemab Therapeutics in a research note on Thursday, October 15th. They issued an “overweight” rating and a $70.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Hemab Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.71.

Hemab Therapeutics Trading Down 1.5%

Hemab Therapeutics stock opened at $34.81 on Friday. The company has a 50 day moving average of $39.42. Hemab Therapeutics has a 1 year low of $23.00 and a 1 year high of $55.42.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). On average, research analysts forecast that Hemab Therapeutics will post -3.10 EPS for the current year.

Institutional Investors Weigh In On Hemab Therapeutics

A number of institutional investors have recently modified their holdings of COAG. State Street Corp purchased a new position in Hemab Therapeutics during the 2nd quarter valued at about $2,825,000. Opaleye Management Inc. acquired a new position in Hemab Therapeutics in the 2nd quarter valued at about $1,750,000. The Manufacturers Life Insurance Company acquired a new position in Hemab Therapeutics in the 2nd quarter valued at about $688,000. Squarepoint Ops LLC acquired a new position in Hemab Therapeutics in the 2nd quarter valued at about $230,000. Finally, Citadel Advisors LLC purchased a new stake in Hemab Therapeutics during the second quarter worth about $19,226,000.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.

Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.